We and others have recently found that mature murine B cells can be induced to undergo apoptosis, in vitro, in a dose-dependent manner, by extensive crosslinking of membrane IgM with polyclonal anti-µ. During the analysis of tolerance in transgenic mice expressing rearranged IgM or IgM + IgD receptors, we observed that, Sp6 anti-TNP Ig and anti-MHC transgenic splenocytes, would undergo receptor-mediated apoptosis in vitro just like their normal, non-transgenic littermates. However, transgenic mice expressing rearranged receptors typical of B1 cells, not only contained large numbers of CD5 + cells in their spleens, but these cells failed to undergo apoptosis under conditions that led to programmed cell death in normal splenocytes. B1 spleen cells also failed to proliferate with anti-IgM, although the responsiveness of cells from the other transgenic lines varied depending on the background strains. These differences are due in part, to strain differences, but they also imply that the response pattern of transgenic B cells reflects not only the subset composition in this organ, but also the transgenic specificity of the receptor.
INTRODUCTION
Two distinct subsets of B cells have been described in mice and humans: the conventional B cell, predominant in the spleen and lymph nodes, and the B1 (CD5 + ) cell, which comprises the majority of B cells in the peritoneum (>85%). B1 cells, which are prevalent early in ontogeny and possibly play a role in B-cell repertoire maturation, have been shown to express polyvalent, low affinity antibodies with self-reactivity (1) and have been linked to several autoimmune diseases (2) . We (3, 4) have previously shown that B1 cells are resistant to tolerance protocols involving crosslinking of sIgM that lead to hyporesponsiveness of conventional B cells. B1 cells, however, can be rendered hyporesponsive to LPS challenge by ionomycin or activation of protein kinase C with phorbol esters, for example, suggesting that ___________________________________________ Received: 3/29/96, Accepted: 6/25/96 1 To whom correspondence should be addressed, at American Red Cross Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA Tel #: (301) 517-0335, Fax #: (301) 517-0344, Email: scottd@hlsun.red-cross.org B1 cells are defective in a calcium-dependent protein kinase C pathway (4, 5) . In this communication, we compare the ability of B1 and conventional B cells to undergo programmed cell death (PCD) via apoptosis, and proliferation in response to sIgM crosslinking. To examine this, we used transgenic mice that either express rearranged receptors typical of the B1 repertoire, or rearranged receptors typical of con-ventional B cells; spleens from the B1 transgenic mice contain primarily cells of the B1/CD5 + type, unlike their normal counterparts. We have previously shown that the defect in signaling in murine B1 cells is not related to their location in vivo, but rather to differences in membrane signaling (4) . It is these differences, and how they relate to PCD, that are of interest.
MATERIALS AND METHODS

Animals.
All transgenic animals used are lines previously described (4 Cell preparation, proliferation and apoptosis assays. Splenic single cell suspensions were obtained and red cells removed as described previously (3) (4) (5) . Viable cell counts were performed using trypan blue exclusion, and suspensions were normalized to 5 x 10 6 cells per ml. Unless otherwise noted, all spleens were processed individually, in parallel, on a given day.
Proliferation assays were performed as described earlier (5) . Briefly, cells were cultured in 96 well tissue culture plates at 37 o C, 7% CO2, at 5x10 5 + populations. After fixation, cells were then washed twice with cold PBS and resuspended in one ml PBS containing 10 µg/ml RNase (Sigma) for 30 minutes at 37 o C. Propidium iodide was added to a final concentration of 50 µg/ml, and allowed to equilibrate for ten minutes. Samples were the analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA), using FL2 channel and low flow rate. FL2 area and width were used to gate out doublets, and front scatter and FL2 height were used to gate out debris; a minimum of 10,000 gated cells were collected for each sample. Final data was prepared using gated cells on an FL2 height histogram, with apoptotic cells appearing as a sub 2N population to the left of G0/G1 peak (9).
It should be noted that the numbers of B cells in each line was relatively constant, ranging from 38-65%, although the 6.1 line possessed a large number of B220 low cells, typical of the CD5 subset.
RESULTS
Transgenic mice, expressing IgM receptors typical of either B1 or conventional B cells, were used to compare susceptibility of these B cell types to the induction of PCD by anti-IgM. We used three lines of transgenics, one expressing IgM receptors typically of the B1 repertoire, and two lines expressing receptors typical of conventional B cells. In each case, we used nontransgenic littermates for each line as controls, as well as normal C57Bl/6 x DBA/2J F1 (B6D2) mice. In particular, line 6.1 spleen cells expressed >96% of the CH27 VH12 idiotype seen in peritoneal B1 cells, whereas the 3.83 and Sp6 lines contained primarily conventional (B2) cells in the spleen. Importantly, more than 66-75% of splenic B cells in line 6.1 mice are CD5 + , the remainder having the characteristics of B1 "sister cells" (4) . Therefore, this allows us to compare splenic populations from different IgM transgenic lines in terms of their susceptibility to antiIgM-induced apoptosis and eliminates problems associated with purification of peritoneal B cells. The standard protocol of hyper-crosslinking sIgM with anti-µ specific goat antibodies, followed by a 24 hour incubation period (9, 10) was employed. Cultures were then examined by FACScan® for apoptotic B-cell populations after gating on B220 + cells. The results in Figure 1 -2 summarize the observed differences.
Susceptibility of Sp6 anti-TNP transgenic B cells to programmed cell death with anti-µ µ.
It has been reported that the majority of splenic B cells in the Sp6 anti-TNP line are transgenic, CD5 -, and express IgM and B220 at levels typical of normal splenic B cells. This phenotype suggests that these transgenic B cells are of the conventional B2 cell type (4, 8, 12) , except that they do not express sIgD due to lack of endogenous rearrangements. We have shown in prior studies that splenic B cells from these animals can be rendered unresponsive to subsequent challenge through sIgM crosslinking in a manner similar to non-transgenic conventional B cells (4) . Moreover, Carsetti and colleagues demonstrated that Sp6 B cells would undergo programmed cell death, in vivo and in vitro, with a specific antigen like TNP-dextran (12) . This suggests an intact and functioning membrane IgM signaling pathway. We report here that Sp6 splenic B cells also undergo induced PCD in a normal, dose-dependent manner ( Figure  1 middle) . In repeat experiments, the dose response curves for Sp6 transgenic B cells were similar to both nontransgenic littermates and B6D2 controls (Figure 1 left and data not shown). 
Susceptibility of 3.83 anti-MHC transgenic B cells to programmed cell death with anti-µ µ.
The results above suggest that transgenic anti-TNP specific B cells respond normally to hypercrosslinking signals with anti-µ. It was important to repeat these experiments in another transgenic strain expressing Ig receptors of a different specificity. We chose to use the 3.83 anti-MHC transgenic line both because it had been used previously to demonstrate deletion of the developing B-cell repertoire (7) and to be susceptible to tolerance in vitro in our anti-µ protocol (4). Spleen cells from 3.83 transgenic and non-transgenic control littermates were treated with anti-µ as above and analyzed for apoptosis. The results in Figure 1 (right) indicate that the anti-MHC transgenics also responded normally to hyper-crosslinking with anti-µ by undergoing PCD, as was seen in B6D2 and Sp6 conventional splenocytes.
VH12 anti-phosphatidyl choline transgenic B cells are resistant to programmed cell death with anti-µ µ.
We have previously reported that VH12 transgenic mice, as well as CH12 transgenics, are resistant to tolerance induction with anti-µ (4). Both strains contain large numbers of B1 cells, either CD5 + or CD5 -"sister" cells in their spleens. To establish the susceptibility of VH12 transgenic B cells to apoptosis, we repeated the anti-µ protocol above. The results in Figure 2 show that VH12 transgenic B1 B cells are relatively resistant to anti-µ-driven PCD. Note that non-transgenic control spleen cells, which possess similar numbers of B cells, examined simultaneously were susceptible to PCD just like the previous conventional strains tested (see Figure 1) . Moreover, this is not simply a difference in dose response curves because a full range of anti-µ concentrations was done in each experiment (Figure 2 ). This suggests that one explanation of the resistance to tolerance of B1 cells is their failure to process the hyper-crosslinking signals that lead to apoptotic cell death. Strain differences in the proliferative response to anti-µ µ.
We previously suggested that initial signaling differences between VH12 (B1) and the conventional transgenic B cells tested could account for differential susceptibility to tolerance induction (4). Moreover, if one bypassed the Ig receptors using phorbol esters or ionomycin (or both), then unresponsiveness ensued. In these experiments, it was not known whether VH12 transgenic B cells (or the other strains tested) were able to proliferate normally to anti-µ. Therefore, we examined splenocytes from all three strains and normal B6D2 F1 mice for their ability to proliferate with polyclonal anti-µ. In these studies, spleen cells are cultured with 3, 10 and 30 µg/ml anti-µ for 44-50 hours in order to drive significant numbers of B cells into cycle. The results in Figure 3 show that VH12 transgenic B cells failed to proliferate with anti-µ, whereas the other transgenic lines were more responsive with peak proliferation at 10 µg/ml. However, it should be 
DISCUSSION
Adult murine spleen cells will undergo dose-, time-and temperature-dependent apoptosis in vitro if sufficient crosslinking of membrane IgM occurs via antiIgM treatment (9) (10) (11) . The data presented herein confirm that mature splenic B cells will be driven to PCD (apoptosis), but differences in the susceptibility of B-cell subsets to apoptosis can be seen in this system. These results are reminiscent of our recent observation of resistance to tolerance induction in murine B1 cells in the peritoneum (3) and the spleen (4). Indeed, these results suggest that the differential susceptibility to tolerance of murine B cells may reflect these signaling differences for apoptosis. Immunoglobulin receptor crosslinking also is important as the first step in B-cell activation for cell cycle entry (13, 14) . Clearly, the maturity and lineage of the target B cells, as well as second signals like CD40 and cytokines, play a role in driving B-cell proliferation (15, 16) . The data presented herein indicate that strain and subset differences also play a role in B-cell apoptosis.
Crosslinking of membrane IgM causes initial tyrosine phosphorylation of a number of substrates, as well as phosphatidyl inositol hydrolysis, calcium mobilization and downstream effector events to lead to exit from G0 and entry into the cell cycle (17) . In our experience, the ability to drive B-cell proliferation and apoptosis generally do not correlate. For example, mitogenic monoclonal anti-µ reagents do not induce apoptosis unless hyper-crosslinked (9, 10), yet such antibodies can drive resting B cells into cycle reproducibly. Moreover, CD45 knockout mice (18), which can not be driven into cycle with any form of anti-µ, are nonetheless susceptible to apoptosis induced by goat anti-µ. (9) . Finally, xid mice show the same separation of proliferation and apoptosis: anti-µ induces PCD but can not drive xid B cells into S (19) . Therefore, the ability to drive apoptosis and cell cycle entry, even abortively, does not correlate.
Interestingly, in CD45 knockout and xid spleen cells (9, 19) , anti-µ causes a reduction in the p27 kinase inhibitor (20) known to regulate cell cycle entry in other cell types. It will be important to discern whether the anti-µ signaling defect is upstream or downstream from p27 modulation in 6.1 transgenic B cells. These studies are planned.
Our results are contrary to previously published data (21) suggesting normal proliferation in response to soluble anti-IgM in Sp6, but not M167 transgenic mice, which are predominantly B2-like in the spleen. Several differences between these studies should be noted. First, very high doses of different antibodies were used to induce proliferation in their system (21); indeed, in our hands, polyclonal anti-µ at >10 µg/ml induces extensive B-cell PCD and minimal proliferation. However, a more likely explanation is that the background genes for these transgenic strains may differ (C57Bl vs. Balb/c). In both their studies and ours, transgenic B cells did proliferate normally in response to LPS and PWM. These data suggest that the differences noted may be downstream from initial tyrosine phosphorylation events (3, 4) since this event is relatively normal in Sp6 and 3.83 transgenics, and only modestly affected in 6.1 transgenic B cells (4) .
Clearly, further studies are necessary to pinpoint the defect(s) leading to diminished B-cell apoptosis and proliferation in 6.1 transgenic B1-type cells compared to conventional B cells. Nonetheless, our results suggest that one reason for the resistance of B1 cells to tolerance induction is a failure to undergo apoptosis when their surface IgM is sufficiently crosslinked.
